Lead program: Preclinical

BetterLife PharmaCSE: BETR

CategoriesEarly-Stage Translational Research (Pre-Clinical)Research, Drug Development & Manufacturing

Data updated July 15, 2026

1 Drug Candidate

Enterprise Intelligence

Quarterly psychedelic drug-development briefing

Compare indication activity, programme milestones, competitive intensity, and near-term catalysts. Q2 includes quarter-over-quarter changes against the published Q1 baseline.

Browse briefings Open Q2 briefing

BetterLife Pharma (CSE: BETR / OTC: BETRF) is a Canadian biotech developing BETR-001, a first-in-class non-hallucinogenic LSD derivative (2-bromo-LSD / BOL-148) for MDD, anxiety, and neuropathic pain. BETR-001 was acquired from Transcend Biodynamics LLC and activates the 5-HT2A receptor at 60% efficacy — sufficient for neuroplastogenic antidepressant effects but below the threshold for hallucinogenic effects. A composition of matter patent was granted January 2025, IND filing projected H1 2026.

Pipeline Intelligence

Developer Momentum

Programme tracker

Active candidates: 1
Active programmes: 1
Lead stage: Preclinical
Forecast coverage: 1 of 1

Latest sourced update

BetterLife engages Syner-G for BETR-001 GMP manufacturing toward IND and Phase 1

Jun 25, 2026 - Press release - BetterLife Pharma / Newsfile - BETR-001

Next known catalyst

Regulatory filing submitted

Q1 2027 - BETR-001 / BETR-001 IND-Enabling Programme (MDD/Anxiety/Cluster Headache) - Confidence: 50%

8 sources0 pipeline-linked trials0 pipeline-linked papers

Development Programmes

BETR-001

Preclinical

Major Depressive Disorder (MDD)Anxiety Disorders

BETR-001 is 2-bromo-LSD / 2-Br-LSD, a non-hallucinogenic LSD derivative and neuroplastogen now being advanced initially for chronic cluster headache and chronic migraine, while retaining broader psychiatric and neurological potential. BetterLife secured CAD $2M in June 2026 for remaining IND-enabling work and engaged Syner-G to oversee GMP manufacturing; company guidance now points to IND filing and Phase 1 start in Q1 2027.

Major Depressive Disorder (MDD)

Primary: US (FDA)

Pre-clinicalActive

Forecast

Regulatory filing submitted - Likely: Q1 2027

BETR-001 remains in final IND-enabling development. BetterLife closed CAD $2M financing on 2026-06-22 to fund remaining FDA IND work, then engaged Syner-G on 2026-06-25 to oversee GMP manufacturing for the planned IND and Phase 1 programme. The initial clinical focus has shifted to chronic cluster headache and chronic migraine, with IND filing and Phase 1 start projected for Q1 2027.

Milestones

Pre-clinical completed

Completed

Actual: Oct 23, 2024

GLP genotoxicity study completed: no bone marrow toxicity, no mutagenic or clastogenic activity for oral BETR-001

Why it matters: Clean genotoxicity data is a critical IND-enabling milestone. BETR-001 is a 5-HT2A partial agonist (~60% activation vs LSD's ~90%) that produces neuroplastogenic effects without hallucinogenic activity. The genotox clearance removes a key regulatory risk.

Watch next: IND filing H2 2026

BetterLife obtains favourable genotoxicity data for oral BETR-001(Press release)[Verified]

Pre-clinical completed

Completed

Actual: Nov 25, 2024

Favorable cardiac safety data: minimal hERG channel impact — low cardiac arrhythmia risk

Why it matters: hERG safety is the second critical IND-enabling gate after genotoxicity. Minimal hERG impact means BETR-001 has a clean cardiovascular safety profile, differentiating it from compounds with QT prolongation liability.

BetterLife obtains favourable cardiac safety data for BETR-001(Press release)[Verified]

Funding milestone

Completed

Actual: Apr 3, 2024

Closed $1.168M convertible debentures to fund IND-enabling studies for BETR-001

Why it matters: BetterLife is a micro-cap (CSE:BETR, ~$9.4M market cap) funding development via convertible debentures rather than VC — a scrappy approach that preserves equity but limits speed. The $1.168M funds the critical IND-enabling tox studies.

BetterLife secures CAD2M financing to complete BETR-001 IND-enabling work(News / media)[Verified]

Company milestone

Completed

Actual: Jan 1, 2025

USPTO composition of matter patent granted for BETR-001

Why it matters: Patent protection secures exclusivity for the specific (6R,9R) 2-bromo-LSD hemi-tartrate stereoisomer. Non-controlled substance status plus patent protection creates a favorable regulatory and commercial landscape.

BetterLife provides BETR-001 mechanism-of-action update(Press release)[Verified]BetterLife engages Syner-G for BETR-001 GMP manufacturing toward IND and Phase 1(Press release)[Verified]

Recorded Events

Jan 1, 2025: Company milestone

Nov 25, 2024: Pre-clinical completed

Oct 23, 2024: Pre-clinical completed

Apr 3, 2024: Funding milestone